Evotec, Bristol Myers Squibb win FDA clearance for second drug candidate to enter clinical trials
EVO•Evotec received FDA clearance on November 19 for a second drug candidate from its protein degradation partnership with Bristol Myers Squibb. The molecular glue candidate is expected to enter a Phase 1 trial in 2027.
1. Second candidate cleared
Evotec said the FDA cleared a second drug candidate from its protein degradation partnership with Bristol Myers Squibb on November 19, 2026. The molecular glue candidate is expected to enter a Phase 1 clinical trial in 2027, expanding the partnership’s clinical pipeline.
2. First candidate in trial
The partnership’s first candidate entered a Phase 1 trial in March 2026 for advanced clear cell renal cell carcinoma.




